RSS
Consumer News
Consumer Reports
Trusted reliable news sources from around the web. We offer special news reports, topic news videos, and related content stories. Truly a birds eye view on news.
Consumer Resources
- Details
- Written by Bing News Search Results
- Category: Vehicle News Articles
Experience the incredible journey of a master craftsman as he constructs a custom electric car from the ground up using woodworking and engineering expertise. Watch as the metal chassis is transformed ...
Original Image Link
Source:www.msn.com
Original Image Link
Source:www.msn.com
- Details
- Written by CNET Reviews
- Category: Reviews
Save $51: With GTA 6 on the horizon, there’s never been a better time to upgrade your PS5 and pick up a pair of PlayStation Pulse Explore earbuds — they’re on sale today for just $149, their lowest-ever price.
Photo By CNET
Photo By CNET
- Details
- Written by CNET Reviews
- Category: Reviews
Whether you’re showing off your new tech this fall or looking for a holiday gift, a Google Pixel watch could be a thoughtful pick. It fits right into the Google ecosystem, working with Pixel phone and other devices to help track your health and more. The latest Pixel Watch 5 builds on the momentum, making…
Photo By CNET
Photo By CNET
- Details
- Written by CNET Reviews
- Category: Reviews
Save $23: Logitech’s Keys-to-Go portable keyboard is on sale for just $57 currently, its lowest price of the year. This deal only applies to the white version, so you’ll pay more for the black or purple models.
Photo By CNET
Photo By CNET
- Details
- Written by Consumer Affairs News
- Category: Consumer Daily Reports
of ConsumerAffairs
October 12, 2026
A new Cochrane review links drug company gifts and payments to more prescriptions, less appropriate prescribing and probably higher costs.
Even inexpensive meals were associated with greater prescribing of the sponsoring companys drugs.
Policies restricting industry interactions appear to improve prescribing, although the studies cannot establish that gifts caused the changes.
Free meals, gifts and payments from pharmaceutical companies are associated with changes in the medicines doctors prescribe, according to a new review published by the Cochrane Collaboration.
The researchers examined 93 studies, including 82 conducted in the United States. They found that doctors receiving industry gifts and payments wrote more prescriptions and prescribed less appropriately than those with fewer or no such interactions. Prescription costs may have also been higher, the researchers said.
Drug companies promote their products through sales representative visits, sponsored education, meals, travel expenses, consulting fees and payments for serving on advisory boards. Those relationships can steer prescribing toward a companys promoted medicine, which may not be the most suitable or affordable option, Cochrane said.
The findings extended across several drug categories, including medicines for high blood pressure and cholesterol, antidepressants and opioid painkillers. Doctors who received more company-sponsored meals tended to prescribe more of that companys drugs.
Small gifts, meaningful concerns
Lead author Dr. Barbara Mintzes, of the University of Sydney, said physicians often regard free meals as too insignificant to influence their judgment. But the evidence suggests those meals are an effective marketing tool.
Study coauthor Dr. Lisa Bero, of the University of Colorado Anschutz, said the consequences reach beyond spending. She said patients should be offered the most appropriate treatment for their condition, based on clinical evidence not industry marketing.
Cochrane highlighted opioid prescribing as a particularly troubling example: industry payments were associated with a greater likelihood of prescribing dangerously high doses.
Restrictions may help
The review found that conflict-of-interest policies limiting or managing industry interactions probably improve prescribing appropriateness and may reduce prescription volume.
- Details
- Written by Consumer Affairs News
- Category: Consumer Daily Reports
of ConsumerAffairs
October 12, 2026
Johns Hopkins researchers found that GLP-1 drugs promote weight loss across a broad range of patients, with women losing more weight on average than men.
The medications may offer benefits beyond weight loss, but evidence varies depending on the condition and drug.
Side effects, muscle loss and difficulty maintaining treatment remain concerns, particularly for older or frail patients.
GLP-1 medications help a wide range of patients lose weight, according to a Johns Hopkins-led research review that found generally consistent effectiveness across age, race, ethnicity, starting body mass index and average blood sugar levels. Women, however, experienced greater weight loss than men.
The findings, highlighted in a fall Johns Hopkins Magazine article, come as researchers examine both the expanding benefits of these medications and the challenges patients face when taking them over time.
The review, published in JAMA Internal Medicine, included 41 articles representing 64 randomized clinical trials. In six trials involving nearly 20,000 patients analyzed by sex, women lost an average of 10.9% of their starting weight, compared with 6.8% among men.
The findings
Those figures reflect averages across the included trials, rather than a prediction of what an individual patient will lose. The researchers found no statistically significant differences in treatment effects across the other patient characteristics examined.
G. Caleb Alexander, a Johns Hopkins professor of epidemiology and medicine, told the magazine that an interaction with estrogen could help explain the difference between women and men, although that explanation remains unproven.
These drugs are transformativea real game changer, Alexander said.
The magazine also describes research into possible benefits involving addiction, osteoarthritis and cancer risk. Those possibilities should be distinguished from established uses: promising associations do not necessarily demonstrate that a medication caused an improvement.
Some benefits beyond weight management already appear in prescribing information. Wegovy, for example, is approved to reduce major cardiovascular events in adults with established cardiovascular disease and overweight or obesity. Its injectable formulation also has accelerated approval for certain adults with a form of metabolic liver disease and moderate to advanced fibrosis.
Consumer Daily Reports Article Count: 6555
Environmental News Articles Article Count: 32
Reviews Article Count: 2591
Vehicle News Articles Article Count: 995
Related Product Search/Búsqueda de productos relacionados
